T1	Participants 34 65	patients with advanced melanoma
T2	Participants 344 375	patients with advanced melanoma
T3	Participants 470 517	enrolled patients without regard to HLA subtype
T4	Participants 580 616	class-I HLA-A*0201-positive patients
T5	Participants 790 808	93.5% of patients.
T6	Participants 697 807	HLA typing was also performed prospectively in several phase II trials and was available for 93.5% of patients
T7	Participants 932 1020	pretreated patients randomized to 0.3, 3, or 10 mg/kg ipilimumab in four phase II trials
T8	Participants 1330 1362	137 HLA-A*0201-positive patients
T9	Participants 1712 1739	ipilimumab-treated patients
